A citation-based method for searching scientific literature

R Manchanda, M Burnell, A Abdelraheim, M Johnson, A Sharma, E Benjamin, C Brunell, E Saridogan, S Gessler, D Oram, L Side, A N Rosenthal, I Jacobs, U Menon. BJOG 2012
Times Cited: 37







List of co-cited articles
369 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent.
D Gareth R Evans, Fiona Lalloo, Linda Ashcroft, Andrew Shenton, Tara Clancy, Andrew D Baildam, Anne Brain, Penelope Hopwood, Anthony Howell. Cancer Epidemiol Biomarkers Prev 2009
98
51

Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
Susan M Domchek, Tara M Friebel, Christian F Singer, D Gareth Evans, Henry T Lynch, Claudine Isaacs, Judy E Garber, Susan L Neuhausen, Ellen Matloff, Rosalind Eeles,[...]. JAMA 2010
831
51

Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers.
Angela R Bradbury, Comfort N Ibe, James J Dignam, Shelly A Cummings, Marion Verp, Melody A White, Grazia Artioli, Laura Dudlicek, Olufunmilayo I Olopade. Genet Med 2008
66
43

Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer.
Joanna B Madalinska, Judith Hollenstein, Eveline Bleiker, Marc van Beurden, Heiddis B Valdimarsdottir, Leon F Massuger, Katja N Gaarenstroom, Marian J E Mourits, René H M Verheijen, Eleonora B L van Dorst,[...]. J Clin Oncol 2005
165
43

Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
Karoline B Kuchenbaecker, John L Hopper, Daniel R Barnes, Kelly-Anne Phillips, Thea M Mooij, Marie-José Roos-Blom, Sarah Jervis, Flora E van Leeuwen, Roger L Milne, Nadine Andrieu,[...]. JAMA 2017
803
37

Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.
Amy Finch, Mario Beiner, Jan Lubinski, Henry T Lynch, Pal Moller, Barry Rosen, Joan Murphy, Parviz Ghadirian, Eitan Friedman, William D Foulkes,[...]. JAMA 2006
388
35

Meta-analysis of BRCA1 and BRCA2 penetrance.
Sining Chen, Giovanni Parmigiani. J Clin Oncol 2007
32

Risk-reducing mastectomy and salpingo-oophorectomy in unaffected BRCA mutation carriers: uptake and timing.
A-B Skytte, A-M Gerdes, M K Andersen, L Sunde, K Brøndum-Nielsen, M Waldstrøm, S Kølvraa, D Crüger. Clin Genet 2010
72
32

Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers.
Mary S Beattie, Beth Crawford, Feng Lin, Eric Vittinghoff, John Ziegler. Genet Test Mol Biomarkers 2009
63
29

Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
Noah D Kauff, Jaya M Satagopan, Mark E Robson, Lauren Scheuer, Martee Hensley, Clifford A Hudis, Nathan A Ellis, Jeff Boyd, Patrick I Borgen, Richard R Barakat,[...]. N Engl J Med 2002
863
29

International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers.
Kelly A Metcalfe, Daphna Birenbaum-Carmeli, Jan Lubinski, Jacek Gronwald, Henry Lynch, Pal Moller, Parviz Ghadirian, William D Foulkes, Jan Klijn, Eitan Friedman,[...]. Int J Cancer 2008
241
29

Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.
Noah D Kauff, Susan M Domchek, Tara M Friebel, Mark E Robson, Johanna Lee, Judy E Garber, Claudine Isaacs, D Gareth Evans, Henry Lynch, Rosalind A Eeles,[...]. J Clin Oncol 2008
350
29

The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation.
A Finch, K A Metcalfe, J K Chiang, L Elit, J McLaughlin, C Springate, R Demsky, J Murphy, B Rosen, S A Narod. Gynecol Oncol 2011
126
29

The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy.
Joanna B Madalinska, Marc van Beurden, Eveline M A Bleiker, Heiddis B Valdimarsdottir, Judith Hollenstein, Leon F Massuger, Katja N Gaarenstroom, Marian J E Mourits, René H M Verheijen, Eleonora B L van Dorst,[...]. J Clin Oncol 2006
142
29

Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction.
B A M Heemskerk-Gerritsen, C Seynaeve, C J van Asperen, M G E M Ausems, J M Collée, H C van Doorn, E B Gomez Garcia, C M Kets, F E van Leeuwen, H E J Meijers-Heijboer,[...]. J Natl Cancer Inst 2015
114
27

Predictors of prophylactic bilateral salpingo-oophorectomy compared with gynecologic screening use in BRCA1/2 mutation carriers.
Joanna B Madalinska, Marc van Beurden, Eveline M A Bleiker, Heiddis B Valdimarsdottir, Lottie Lubsen-Brandsma, Leon F Massuger, Marian J E Mourits, Katja N Gaarenstroom, Eleonora B L van Dorst, Hans van der Putten,[...]. J Clin Oncol 2007
54
24

Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.
Mary-Claire King, Joan H Marks, Jessica B Mandell. Science 2003
24

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
A Antoniou, P D P Pharoah, S Narod, H A Risch, J E Eyfjord, J L Hopper, N Loman, H Olsson, O Johannsson, A Borg,[...]. Am J Hum Genet 2003
24

Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
Timothy R Rebbeck, Tara Friebel, Henry T Lynch, Susan L Neuhausen, Laura van 't Veer, Judy E Garber, Gareth R Evans, Steven A Narod, Claudine Isaacs, Ellen Matloff,[...]. J Clin Oncol 2004
697
24

Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
Timothy R Rebbeck, Henry T Lynch, Susan L Neuhausen, Steven A Narod, Laura Van't Veer, Judy E Garber, Gareth Evans, Claudine Isaacs, Mary B Daly, Ellen Matloff,[...]. N Engl J Med 2002
998
21

Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status.
R Manchanda, A Abdelraheim, M Johnson, A N Rosenthal, E Benjamin, C Brunell, M Burnell, L Side, S Gessler, E Saridogan,[...]. BJOG 2011
72
21

Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.
Nasim Mavaddat, Susan Peock, Debra Frost, Steve Ellis, Radka Platte, Elena Fineberg, D Gareth Evans, Louise Izatt, Rosalind A Eeles, Julian Adlard,[...]. J Natl Cancer Inst 2013
485
21

Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation.
Amy P M Finch, Jan Lubinski, Pål Møller, Christian F Singer, Beth Karlan, Leigha Senter, Barry Rosen, Lovise Maehle, Parviz Ghadirian, Cezary Cybulski,[...]. J Clin Oncol 2014
331
21


No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study.
B B J Hermsen, R I Olivier, R H M Verheijen, M van Beurden, J A de Hullu, L F Massuger, C W Burger, C T Brekelmans, M J Mourits, G H de Bock,[...]. Br J Cancer 2007
95
18

Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy.
Mark Robson, Martee Hensley, Richard Barakat, Carol Brown, Dennis Chi, Elizabeth Poynor, Kenneth Offit. Gynecol Oncol 2003
97
18

Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
Timothy R Rebbeck, Tara Friebel, Theresa Wagner, Henry T Lynch, Judy E Garber, Mary B Daly, Claudine Isaacs, Olufunmilayo I Olopade, Susan L Neuhausen, Laura van 't Veer,[...]. J Clin Oncol 2005
262
18

BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.
Kathryn Alsop, Sian Fereday, Cliff Meldrum, Anna deFazio, Catherine Emmanuel, Joshy George, Alexander Dobrovic, Michael J Birrer, Penelope M Webb, Colin Stewart,[...]. J Clin Oncol 2012
674
18

Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing.
Ranjit Manchanda, Rosa Legood, Matthew Burnell, Alistair McGuire, Maria Raikou, Kelly Loggenberg, Jane Wardle, Saskia Sanderson, Sue Gessler, Lucy Side,[...]. J Natl Cancer Inst 2014
97
18

Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial.
Ranjit Manchanda, Kelly Loggenberg, Saskia Sanderson, Matthew Burnell, Jane Wardle, Sue Gessler, Lucy Side, Nyala Balogun, Rakshit Desai, Ajith Kumar,[...]. J Natl Cancer Inst 2014
102
18

Cluster-randomised non-inferiority trial comparing DVD-assisted and traditional genetic counselling in systematic population testing for BRCA1/2 mutations.
Ranjit Manchanda, Matthew Burnell, Kelly Loggenberg, Rakshit Desai, Jane Wardle, Saskia C Sanderson, Sue Gessler, Lucy Side, Nyala Balogun, Ajith Kumar,[...]. J Med Genet 2016
26
26

Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses' health study.
William H Parker, Diane Feskanich, Michael S Broder, Eunice Chang, Donna Shoupe, Cynthia M Farquhar, Jonathan S Berek, JoAnn E Manson. Obstet Gynecol 2013
247
18

International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation.
Kelly Metcalfe, Andrea Eisen, Leigha Senter, Susan Armel, Louise Bordeleau, Wendy S Meschino, Tuya Pal, Henry T Lynch, Nadine M Tung, Ava Kwong,[...]. Br J Cancer 2019
40
18


Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing.
Marc D Schwartz, Elizabeth Kaufman, Beth N Peshkin, Claudine Isaacs, Chanita Hughes, Tiffani DeMarco, Clinton Finch, Caryn Lerman. J Clin Oncol 2003
95
16

Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Anne Uyei, Susan K Peterson, Julie Erlichman, Kristine Broglio, Sandra Yekell, Kathkeen Schmeler, Karen Lu, Funda Meric-Bernstam, Chris Amos, Louise Strong,[...]. Cancer 2006
47
16

Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation.
E J Meijers-Heijboer, L C Verhoog, C T Brekelmans, C Seynaeve, M M Tilanus-Linthorst, A Wagner, L Dukel, P Devilee, A M van den Ouweland, A N van Geel,[...]. Lancet 2000
224
16


Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women.
Kelly A Metcalfe, Aletta Poll, Robert Royer, Marcia Llacuachaqui, Anna Tulman, Ping Sun, Steven A Narod. J Clin Oncol 2010
110
16

Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers.
Tara M Friebel, Susan M Domchek, Susan L Neuhausen, Theresa Wagner, D Gareth Evans, Claudine Isaacs, Judy E Garber, Mary B Daly, Rosalind Eeles, Ellen Matloff,[...]. Clin Breast Cancer 2007
53
16

Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers.
Claudia Marchetti, Francesca De Felice, Innocenza Palaia, Giorgia Perniola, Angela Musella, Daniela Musio, Ludovico Muzii, Vincenzo Tombolini, Pierluigi Benedetti Panici. BMC Womens Health 2014
86
16

Risk management options elected by women after testing positive for a BRCA mutation.
Christine Garcia, Jacqueline Wendt, Liisa Lyon, Jennifer Jones, Ramey D Littell, Mary Anne Armstrong, Tina Raine-Bennett, C Bethan Powell. Gynecol Oncol 2014
60
16

Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study.
William H Parker, Michael S Broder, Eunice Chang, Diane Feskanich, Cindy Farquhar, Zhimae Liu, Donna Shoupe, Jonathan S Berek, Susan Hankinson, JoAnn E Manson. Obstet Gynecol 2009
402
16

Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer.
Marc D Schwartz, Heiddis B Valdimarsdottir, Beth N Peshkin, Jeanne Mandelblatt, Rachel Nusbaum, An-Tsun Huang, Yaojen Chang, Kristi Graves, Claudine Isaacs, Marie Wood,[...]. J Clin Oncol 2014
151
16

A risk prediction algorithm for ovarian cancer incorporating BRCA1, BRCA2, common alleles and other familial effects.
Sarah Jervis, Honglin Song, Andrew Lee, Ed Dicks, Patricia Harrington, Caroline Baynes, Ranjit Manchanda, Douglas F Easton, Ian Jacobs, Paul P D Pharoah,[...]. J Med Genet 2015
33
18

Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study.
Phuong L Mai, Marion Piedmonte, Paul K Han, Richard P Moser, Joan L Walker, Gustavo Rodriguez, John Boggess, Thomas J Rutherford, Oliver Zivanovic, David E Cohn,[...]. Gynecol Oncol 2017
14
42

Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial.
Saundra S Buys, Edward Partridge, Amanda Black, Christine C Johnson, Lois Lamerato, Claudine Isaacs, Douglas J Reding, Robert T Greenlee, Lance A Yokochi, Bruce Kessel,[...]. JAMA 2011
710
13

Psychological impact of prophylactic oophorectomy in women at increased risk of developing ovarian cancer: a prospective study.
K Tiller, B Meiser, P Butow, M Clifton, B Thewes, M Friedlander, K Tucker. Gynecol Oncol 2002
50
13

Acceptance of preventive surgeries by Israeli women who had undergone BRCA testing.
Vardit Kram, Tamar Peretz, Michal Sagi. Fam Cancer 2006
23
21


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.